CareValidate Unveils Enhanced HRT Offering to Support the Next Generation of Telehealth Companies Building in the Women’s Health Space

The Clinical Pathway Equips Telehealth Brands With the Compliant Infrastructure to Serve Perimenopause and Menopause Patients After Decades of Neglect

ATLANTA--(BUSINESS WIRE)--CareValidate, the compliance and clinical infrastructure behind some of the fastest-growing telehealth brands in the country, today announced the launch of its expanded Menopause / Perimenopause Hormone Replacement Therapy (HRT) pathway, a comprehensive offering optimized for both the patient and provider experience. The pathway gives telehealth brands, employers, and healthcare businesses a fully compliant path to serve the fast-growing perimenopause and menopause market, extending CareValidate's existing infrastructure (which already supports programs for menopause, weight loss, longevity & wellness, dermatology, erectile dysfunction, and more) and furthering its commitment to one of the largest underserved categories in women's health.

Women navigating perimenopause and menopause are at the start of a health journey that can last anywhere from 10 to 20 years, and that can impact a number of areas, including their hormones, metabolism, sexual wellness, bone health, mental clarity, and more. However, despite being a routine part of women’s health experienced by over 2 million more U.S. women annually, for decades, the medical system has treated perimenopause and menopause as largely unaddressable.

Misinformation has perpetuated and widened this gap; after a 2002 study linked HRT to breast cancer contributed to the fewer than 25% of eligible women choosing to take HRT today – despite the fact that the FDA disproved this in 2025, and removed black box warning labels from menopausal HRT products. As more women learn that HRT is safe and appropriate for them, demand for treatment is growing, and telehealth is emerging as a major channel for accessing hormone therapy. At the same time, today’s market is increasingly crowded, and the opportunity now is to make that access not only convenient, but clinically sound and compliant.

CareValidate provides the infrastructure behind these programs, helping operators build and scale telehealth HRT offerings with the clinical and regulatory support needed. Operators can launch hormone therapy including progesterone, DHEA, DHEA/pregnenolone, and estradiol in a range of delivery methods, supported by the same licensed provider network and pharmacy fulfillment that CareValidate already uses for its other programs. In addition, HRT represents an entry point for operators hoping to build trust with patients. Once a patient feels they can rely on a brand for hormone care, they often trust the same brand to support other areas of their health, from metabolic to longevity to sexual wellness.

"Women experiencing perimenopause and menopause have been told for too long that their symptoms are just something to live with,” says Dr. Jiten Chhabra, Founder and Chief Medical Officer of CareValidate. “Telehealth is helping expand access to care for this population, but as more of that care moves outside the traditional insurance system, there’s understandable skepticism around cash-pay models. Healthcare shouldn’t be split between insurance-governed care on one side and care with no oversight at all. Cash-pay telehealth should have access to the same infrastructure around safety and compliance as anyone else in this industry – and building those resources in from the start helps facilitate access to the high-quality care this population deserves."

As with each new therapy area CareValidate takes on, HRT was built around the specific clinical and regulatory needs of hormone therapy itself, rather than a one-size-fits-all model. This standard underpins the HRT launch and will continue to guide CareValidate as it expands into additional areas of care.

“I've spent thirty years watching women get dismissed, or told their symptoms are due to aging; all because of a flawed study and a culture of erasing women’s experiences in healthcare," says Dr. Angela DeRosa, DO, MBA, CPE, known to her patients as "Dr. Hotflash." "Our understanding of the ‘real data’ has made significant progress, with proof that hormone replacement therapy is not only effective but safe when prescribed properly. However, easing and expanding women's paths to care still has a long way to go. That's the gap CareValidate is closing.”

CareValidate's expanded HRT pathway is now available for businesses offering hormone replacement therapy for the first time, as well as for partners looking to elevate their services or optimize an existing HRT program. For more information or to get started, please visit https://www.carevalidate.com/categories/menopause

About CareValidate:

CareValidate is the compliance infrastructure behind some of the fastest-growing telehealth brands in the country, including care pathways in menopause, weight loss, longevity & wellness, dermatology, and erectile dysfunction. The platform gives digital health companies, retailers, and wellness brands everything needed to launch and scale virtual care compliantly, from a nationwide licensed provider network and pharmacy fulfillment to AI-powered patient engagement, lab diagnostics, and an API-first architecture that integrates with existing systems. With HIPAA, SOC 2 Type II, and LegitScript compliance built into the platform from the ground up, CareValidate helps telehealth brands go live in an average of 30 days and achieve 3:1 ROI in the first year. Learn more at carevalidate.com.